Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Terminated

Stanbio TDM/B-Hydroxybutyrate Tri-Level Controls, Ref. No. 2460-605

FDA Recall Z-0404-2022 · Posted None

Recall StatusTerminated
Product CodeDIF
Date Initiated2021-11-30
Date Terminated2023-01-06
Product Quantity14 units (individual)

Reason for Recall

Affected product was shipped from the warehouse at room temperature instead of the required refrigerated environment.

Firm Action

The firm distributed an Urgent Recall Notification, dated 11/30/2021, to customers who purchased recalled product via first class mail. The notification informs customers that the firm is initiating a removal of Trilevel Serum Matrix Free from S-O2460605 kits due to product being compromised during shipment. Customers are instructed to immediately check their stock for affected product, quarantine any lot numbers associated with the recall, and destroy affected product. Customers were provided an Urgent Remedial Action Destruction Form to complete and return to the firm to indicate whether or not they possess recalled product and document product destruction. Completed forms are to be returned to the firm via email at [email protected] or by fax at 866-767-1290. If product was further distributed, customers are required to share the recall notification down the distribution chain. Customers with any questions about the recall are instructed to call 866-359-1704.

Root Cause

Storage

Distribution Pattern

US Nationwide distribution in the states of IL, OH, MS, and PA.

Official Source

View FDA Recall →

Source: FDA Enforcement Report / Recall database. Always confirm against the official FDA record.

↑